MedPath

albuphine HCl ER Tablets in Hemodialysis Patients with Uremic Pruritis

Phase 1
Conditions
remic Pruritis in Hemodialysis Patients
MedDRA version: 17.1Level: SOCClassification code 10040785Term: Skin and subcutaneous tissue disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Registration Number
EUCTR2013-005626-29-RO
Lead Sponsor
Trevi Therapeutics, Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
167
Inclusion Criteria

• Subject completed participation in the TR02 study
• Subject is currently receiving in-center hemodialysis at the time of consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 98
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 32

Exclusion Criteria

• Subject receiving or is anticipated to be receiving nocturnal dialysis or home hemodialysis treatment during the study.
• Subject has received opiates on a daily basis during the 1 week prior to Screening
• Other than the TR02 Study Drug, subject received any investigational drug within 4 weeks prior to Screening.
• Subject is a pregnant or lactating female.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath